-

Bayer Statement on Win in Jones Roundup™ Trial

WHIPPANY, N.J.--(BUSINESS WIRE)--On Friday, December 22, a jury reached a defense verdict in the Jones Roundup™ product liability trial before Judge Patrick Palacios in the Superior Court of California, San Benito County, and the Company issued the following statement.

“The jury’s verdict in favor of the Company brings this trial to a successful conclusion and is consistent with the evidence in this case that Roundup™ does not cause cancer and is not responsible for the plaintiff’s illness. The verdict continues the Company’s strong record at trial, winning ten of the last fifteen cases, and validates its strategy of taking cases to trial based on the overwhelming weight of scientific and consistent worldwide regulatory support for the safety of these products.

“We continue to stand behind the safety of Roundup™ and will continue to confidently defend the safety of our products and our good faith actions in future litigation.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Social Media Channels
- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Nicole Hayes
Director, U.S. External Communications
Nicole.Hayes@Bayer.com
(201) 421-5268

Bayer


Release Versions

Contacts

Nicole Hayes
Director, U.S. External Communications
Nicole.Hayes@Bayer.com
(201) 421-5268

More News From Bayer

Federal Judge Remands Monsanto Class Settlement Case Back to MO State Court

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--Today, Judge Henry E. Autrey, a federal district court judge in the Eastern District of Missouri, today issued a ruling remanding the class settlement case, King v Monsanto, back to Missouri State Court. Monsanto released the following statement in response to the Court’s decision. “This decision returns jurisdiction over the class settlement to Missouri Circuit Court where the vast majority of pending claims in the Roundup litigation have been...

Bayer Completes Acquisition of Perfuse Therapeutics

BERLIN--(BUSINESS WIRE)--Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This acquisition strengthe...

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Aleve® announced the launch of its Project DIY Campaign, a new DIY-focused marketing initiative under the recently launched Feel Aleve® platform, featuring HGTV stars, Dave and Jenny Marrs. The activation centers around a home transformation project where Dave and Jenny Marrs renovated a family's back porch, taking a non-functioning space and making it into a space the whole family can use and enjoy and bringing to life what it means to Feel Aleve – up to...
Back to Newsroom